Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer
NACompletedINTERVENTIONAL
Enrollment
10
Participants
Timeline
Start Date
January 31, 2004
Primary Completion Date
December 31, 2007
Conditions
Lung Cancer
Interventions
OTHER
antitumor drug screening assay
Trial Locations (1)
44195
Cleveland Clinic Taussig Cancer Center, Cleveland
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
The Cleveland Clinic
OTHER
NCT00305617 - Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter